Merck & Co. Inc. buy Finanzgonzo
Start price
28.07.11
/
50%
€24.30
Target price
09.01.12
€30.00
Performance (%)
26.55%
End price
09.01.12
€30.16
Summary
This prediction ended on 09.01.12 with a price of €30.16. The prediction had a final performance of 26.55%. Finanzgonzo has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Merck & Co. Inc. | 12.955% | 12.955% | 67.270% | 8.613% |
| iShares Core DAX® | -1.358% | -2.329% | 3.438% | 53.509% |
| iShares Nasdaq 100 | -3.700% | -1.242% | 33.079% | 90.966% |
| iShares Nikkei 225® | -2.512% | 6.914% | 60.778% | 81.100% |
| iShares S&P 500 | -1.662% | -0.643% | 23.467% | 67.066% |
Comments by Finanzgonzo for this prediction
In the thread Merck & Co. Inc. diskutieren
zulassung für victrelis in europa
Merck & Co hat die Zulassung für das Hepatitis C - Medikament Victrelis von der Europäischen Kommission erhalten. Kooperation mit Roche.
Quelle: Der Aktionär Nr. 31 / 2011
(Vom Mitglied beendet)